Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRT-232 in p53 wild-type Merkel cell carcinoma
NL-OMON56137Phase 2Active, not recruiting
- Sponsor
- Kartos Therapeutics
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of navtemadlin and avelumab in Merkel cell carcinoma (MCC) (4 cohorts), sponsored by Kartos Therapeutics. Primary endpoints: Recommended phase 2 dose for Cohort 1 Part 1, Objective response rate for Cohort 1 Part 2 and 4 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
navtemadlinavelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NL-OMON56137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56137.